Navigation Links
The Novel Oral Anticoagulants Will Continue to Drive Growth in the Atrial Fibrillation Drug Market
Date:12/19/2013

BURLINGTON, Mass., Dec. 19, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the atrial fibrillation drug market will experience continued growth through the rest of the decade, increasing from $3.4 billion in 2012 to $8.6 billion in 2020 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. However, generic entry of Boehringer Ingelheim's Pradaxa and Bayer/Janssen's Xarelto will result in contraction of the atrial fibrillation market in the latter part of the 2012 to 2022 forecast period, with the market contracting to $8.1 billion in 2022.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

The Pharmacor advisory service entitled Atrial Fibrillation, which will be published in the days ahead, finds that the novel oral anticoagulants developed for the prevention of stroke in atrial fibrillation patients will continue to drive market growth, accounting for approximately 70 percent market share in 2022. Despite a slow start following its 2013 launch, Bristol-Myers Squibb/Pfizer's Eliquis is expected to be the sales-leading anticoagulant and will garner more than $2.7 billion in 2022. The use of the new anticoagulants will result in a steep decline in sales of warfarin (Bristol-Myers Squibb's Coumadin, Eisai's Warfarin, generics) and other currently available vitamin K antagonists. The anticipated launch of Armetheon's tecarfarin as an anticoagulant therapy for atrial fibrillation patients with mechanical heart valves in the United States will see vitamin K antagonists remain a notable presence in the at
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Mylan Announces Acquisition of Rights to Novel LAMA Respiratory Compound from Pfizer
2. BioLineRx Enters Clinic with Novel Treatment for Celiac Disease
3. ARGX-110, a Novel Anti-CD70 Antibody, Meets Translational Development Goals in Dose Escalation Part of Phase Ib Cancer Study
4. The Market for Non-Small-Cell Lung Cancer (NSCLC) Will Grow to $7 Billion in 2022, Fuelled by the Entry of Twelve Novel Agents
5. The Acute Coronary Syndrome 12-Month Posthospital Market Will Double by 2022, Driven by the Uptake of Novel Lipid Modifying Agents
6. Sutro Biopharma Closes $26 Million Financing, Expands Development of Novel Immuno-Oncology Products
7. High Cost of Biologics and Novel Oral Agents to Treat Immune Diseases Limits Patient Access
8. Opportunity Exists in the U.S. for Novel Agents in Crohns Disease and Ulcerative Colitis, Owing to Discontinued Use of Leading Anti-TNF Agents Driven by Efficacy Failures
9. Synthetic Biologics Enters into License with Cedars-Sinai Medical Center to Develop Novel Anti-infective Approaches for Irritable Bowel Syndrome (IBS), Obesity and Diabetes
10. Bavarian Nordic, the international novel cancer and infectious disease vaccines focused biotech, now covered by Edison.
11. FLAG Therapeutics and Duquesne University Announce Exclusive Worldwide Licensing Agreement for Novel, Dual-action Targeted Oncology Compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 28, 2014  VigeneTech, Inc, in collaboration with ... Data Analysis Software, an OEM software solution for ... develops and offers varieties of bead-based multi-analyte immunoassay ... support of VigeneTech,s data analysis software, FCS data ... easily reported LEGENDplex™ software is ...
(Date:7/28/2014)... 28, 2014  A prospective study conducted by ... has validated the performance of VolparaDensity breast ... associated volumetrically assessed breast density measurements to breast ... & Prevention (DOI: 10.1158/1055-9965.EPI-13-1219), the article, "Automated ... widespread breast cancer risk assessment," was authored by ...
(Date:7/28/2014)... Calif. , July 28, 2014 ... leader in lifestyle healthcare and subsidiary ... that it has acquired Physician Recommended Nutriceuticals (PRN) ... omega-3s, and related products for dry ... Plymouth Meeting, PA, in a transaction worth up ...
Breaking Medicine Technology:VigeneTech Releases New Powerful Software for Flow Cytometry Data Analysis 2Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 2Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 3Karolinska Study Published in Cancer Epidemiology, Biomarkers & Prevention Validates Strong Agreement for VolparaDensity across Mammography Systems from Multiple Manufacturers 4ALPHAEON Acquires PRN, A Leading Specialty Nutriceutical Company 2ALPHAEON Acquires PRN, A Leading Specialty Nutriceutical Company 3
... guide low-income,and minority cancer patients through cancer treatment, ... major obstacles that prevent them,from receiving quality care ... October 28, 2007, at the American Society for ... Angeles. Minority and low-income cancer patients continue ...
... FLUSHING, N.Y., Oct. 30 The following is,being issued by New York Hospital Queens:, ... aureus(MRSA) is scheduled for ... James Rahal, M.D., and a team of infectious disease ... will address the ...
Cached Medicine Technology:Patient Navigators Help Minority, Low-Income Cancer Patients Get Life-Saving Treatments 2Hospital to Hold MRSA Briefing for Media and Community Leaders 2
(Date:7/28/2014)... 28, 2014 Ticket Down is ... Champions Cup Match between Manchester City and Liverpool FC ... Bronx has hosted countless big events since it opened several ... of the original Yankee Stadium, however, it has been a ... City metro area. , The Yankees Stadium is the ...
(Date:7/28/2014)... 2014 A January 2013 study ... intake in those who were self-diagnosed gluten-intolerant yielded little ... nutrition for San Diego health and wellness retreat ... for those who are unclear about the role gluten ... is a protein, found in wheat, barley, rye, and ...
(Date:7/28/2014)... Dawn Echols’ professional background spans ... music. This experience has honed her people skills ... Her professional counseling ( http://dawningphoenix.com ) work includes ... offenders in domestic violence. , As owner ... enjoys counseling individuals and groups for a variety ...
(Date:7/28/2014)... 28, 2014 Ticket Down is ... tickets in Dallas, TX at the Cotton Bowl. The ... the USA and it is an eight team tourney. ... world including teams from La Liga, Serie A, English Premier ... battle it out on the pitch include: Manchester United, ...
(Date:7/28/2014)... Massachusetts (PRWEB) July 28, 2014 ... Summit Provider Exchange technology solution in ... integration efforts and support collaboration with their New ... bed acute-care medical center located in New Jersey, ... seasonal visitors with a variety of inpatient and ...
Breaking Medicine News(10 mins):Health News:Liverpool FC vs. Manchester City Tickets at Yankee Stadium: Ticket Down Reports Huge Demand for Guinness International Champions Cup Tickets in NYC 2Health News:Liverpool FC vs. Manchester City Tickets at Yankee Stadium: Ticket Down Reports Huge Demand for Guinness International Champions Cup Tickets in NYC 3Health News:VeraVia Explains the Basics of Gluten-Intolerance Following Industry Study 2Health News:VeraVia Explains the Basics of Gluten-Intolerance Following Industry Study 3Health News:Dawn M. Echols, M.S., LPC of Dawning Phoenix Speaks at Newly Formed Task Force 2Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Cuts Ticket Prices for AS Roma vs. Real Madrid International Champions Cup Tickets 2Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Cuts Ticket Prices for AS Roma vs. Real Madrid International Champions Cup Tickets 3Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 2Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 3
... ... RXinnovate, a healthcare consultancy, to offer top-of-the-line implementation services to Talyst’s clients in ... ... 44th Annual Midyear Clinical Meeting of the American Society of Health-System Pharmacists in ...
... , ATLANTA, Dec. 7 Results of two ... the antiepileptic drug (AED) Vimpat® for patients requiring add-on therapy ... feasible. These data, which were presented by UCB at ... Boston, further clarify the role of intravenous Vimpat in the ...
... , , NEW ORLEANS, Dec. 7 ... developing novel, proprietary antibodies for the treatment of cancer, ... a poster(1) with new data from its ongoing phase ... patients with non-Hodgkin,s lymphoma (NHL) at the 51ST Annual ...
... , MIAMI, Dec. 7 A couple years ... searching frantically for gifts made in the USA. This fall, ... toys are suspect. Renowned parenting expert Dr. Jeffrey Fine, Ph.D., ... retarding language development and shortening attention spans. Moreover, there is ...
... ... chairman of the board of directors for PerfectServe, a clinical communications company currently serving ... ... Gene Barduson was recently named executive chairman of the board of directors for ...
... , WEST PALM BEACH, Fla., Dec. 7 The ... to publicize the first major innovation in hospital privacy ... is already saving hospitals millions in maintenance costs. , ... Record to elevate Cubicle Curtain Factory,s profile in print, broadcast, ...
Cached Medicine News:Health News:Talyst and RXinnovate Partner on Pharmacy Automation Implementation 2Health News:New Studies Support Use of Intravenous Vimpat(R) (lacosamide) (C-V) in Hospital and Emergency Settings 2Health News:New Studies Support Use of Intravenous Vimpat(R) (lacosamide) (C-V) in Hospital and Emergency Settings 3Health News:New Studies Support Use of Intravenous Vimpat(R) (lacosamide) (C-V) in Hospital and Emergency Settings 4Health News:New Studies Support Use of Intravenous Vimpat(R) (lacosamide) (C-V) in Hospital and Emergency Settings 5Health News:Data from Phase 1 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Non-Hodgkins Lymphoma 2Health News:Data from Phase 1 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Non-Hodgkins Lymphoma 3Health News:Data from Phase 1 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Non-Hodgkins Lymphoma 4Health News:Top 10 Toys That Will Scar Your Child for Life 2Health News:Gene Barduson Named Chairman of PerfectServe Board of Directors 2Health News:Cubicle Curtain Factory Retains TransMedia Group to Promote First Privacy Curtain to Reduce Hospital Maintenance Cost 2
... Simple, cost-effective microfiltration for your transfusion ... also brings you an easy and ... of microfiltration for a variety of ... postoperative applications, autologous or homologous transfusions, ...
This high technology cast plaster cutter saw is very easy and comfortable to use....
... Designed to reduce noise to a minimum ... and less hearing trauma for the clinician. ... high power in a smaller, lighter package. ... saw's balance and ergonomics for more user ...
The True/Fix Cannulated Bone Screw System contains 7.0mm large cannulated bone screws and 3.5mm cortical and 4.0mm cannulated cancellous bone screws....
Medicine Products: